DGS Capital Management’s AstraZeneca AZN Stock Holding History

DGS Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$252K	Buy	1,276 +21	+2%	+$4.05K	0.04%	460
2025 Q4	$231K	Buy	+1,255	New	+$220K	0.04%	413
2022 Q3	–	Sell	-1,913	Closed	-$253K	–	208
2022 Q2	$253K	Sell	1,913 -931	-33%	-$122K	0.2%	129
2022 Q1	$377K	Sell	2,844 -448	-14%	-$53.7K	0.23%	94
2021 Q4	$383K	Buy	+3,292	New	+$387K	0.24%	74

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

DGS Capital Management's AZN Position: Q1 2026 in Review

DGS Capital Management increased its AstraZeneca (AZN) stake by 1.7% in Q1 2026, buying an estimated $4.05K and bringing the position to 1,276 shares worth $252K. The position accounts for 0.04% of the portfolio, ranked #460.

DGS Capital Management first reported a position in AZN in Q4 2021 and has held it in 5 quarters since. The position peaked at $383K in Q4 2021. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

DGS Capital Management held 1,276 shares of AstraZeneca worth $252K as of Q1 2026.
DGS Capital Management bought 21 AstraZeneca shares in Q1 2026, an estimated $4.05K.
AstraZeneca made up 0.04% of DGS Capital Management's portfolio in Q1 2026, its #460 holding.
DGS Capital Management first reported a position in AstraZeneca in Q4 2021 and has held it in 5 quarters since.
DGS Capital Management's AstraZeneca position peaked at $383K in Q4 2021.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on DGS Capital Management's 13F filing for Q1 2026, filed 28 Apr 2026.